跳转至内容
Merck

SML0173

Sigma-Aldrich

Reversan

≥98% (HPLC)

别名:

CBLC4H10, N-[3-(4-Morpholinyl)propyl]-5,7-diphenyl-pyrazolo[1,5-a]pyrimidine-3-carboxamide

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C26H27N5O2
分子量:
441.52
MDL號碼:
分類程式碼代碼:
12161501
PubChem物質ID:
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

顏色

faintly yellow to yellow

溶解度

DMSO: ≥8 mg/mL at ~60 °C

儲存溫度

2-8°C

SMILES 字串

O=C(NCCCN1CCOCC1)c2cnn3c(cc(nc23)-c4ccccc4)-c5ccccc5

InChI

1S/C26H27N5O2/c32-26(27-12-7-13-30-14-16-33-17-15-30)22-19-28-31-24(21-10-5-2-6-11-21)18-23(29-25(22)31)20-8-3-1-4-9-20/h1-6,8-11,18-19H,7,12-17H2,(H,27,32)

InChI 密鑰

JTRXWCLQFAZHGP-UHFFFAOYSA-N

應用

Reversan may be used in cell signaling studies.

生化/生理作用

Reversan increases the efficacy of vincristine and etoposide and increases the sensitivity of murine models of neuroblastoma to conventional chemotherapy.
Reversan is a selective and nontoxic multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp) inhibitor.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Catherine A Burkhart et al.
Cancer research, 69(16), 6573-6580 (2009-08-06)
The multidrug resistance-associated protein 1 (MRP1) has been closely linked to poor treatment response in several cancers, most notably neuroblastoma. Homozygous deletion of the MRP1 gene in primary murine neuroblastoma tumors resulted in increased sensitivity to MRP1 substrate drugs (vincristine
Michelle J Henderson et al.
Journal of the National Cancer Institute, 103(16), 1236-1251 (2011-07-30)
Although the prognostic value of the ATP-binding cassette, subfamily C (ABCC) transporters in childhood neuroblastoma is usually attributed to their role in cytotoxic drug efflux, certain observations have suggested that these multidrug transporters might contribute to the malignant phenotype independent
Katharina Esser-Nobis et al.
Hepatology (Baltimore, Md.), 62(2), 397-408 (2015-04-14)
Hepatitis A virus (HAV) and hepatitis C virus (HCV) are two positive-strand RNA viruses sharing a similar biology, but causing opposing infection outcomes, with HAV always being cleared and HCV establishing persistence in the majority of infections. To gain deeper
Frank Loganzo et al.
Molecular cancer therapeutics, 14(4), 952-963 (2015-02-04)
Antibody-drug conjugates (ADC) are emerging as clinically effective therapy. We hypothesized that cancers treated with ADCs would acquire resistance mechanisms unique to immunoconjugate therapy and that changing ADC components may overcome resistance. Breast cancer cell lines were exposed to multiple

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门